Equities analysts expect that Antares Pharma, Inc. (NASDAQ:ATRS) will report earnings of ($0.03) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at ($0.01). Antares Pharma also reported earnings per share of ($0.03) during the same quarter last year. The company is expected to announce its next earnings report on Tuesday, March 13th.
On average, analysts expect that Antares Pharma will report full year earnings of ($0.11) per share for the current financial year, with EPS estimates ranging from ($0.12) to ($0.10). For the next fiscal year, analysts anticipate that the company will report earnings of $0.00 per share, with EPS estimates ranging from ($0.11) to $0.18. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.01 million. Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The company’s quarterly revenue was up 11.9% on a year-over-year basis.
A number of brokerages have commented on ATRS. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. HC Wainwright reiterated a “buy” rating and set a $3.50 target price on shares of Antares Pharma in a report on Wednesday, November 8th. Piper Jaffray Companies set a $3.00 target price on Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $3.84.
Large investors have recently made changes to their positions in the business. Teachers Advisors LLC acquired a new stake in Antares Pharma during the 2nd quarter valued at $828,000. JPMorgan Chase & Co. lifted its stake in shares of Antares Pharma by 275.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 127,438 shares of the specialty pharmaceutical company’s stock worth $410,000 after purchasing an additional 93,538 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Antares Pharma by 2.0% during the 3rd quarter. Perceptive Advisors LLC now owns 4,353,897 shares of the specialty pharmaceutical company’s stock worth $14,107,000 after purchasing an additional 86,644 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Antares Pharma during the 2nd quarter worth $651,000. Finally, State Street Corp lifted its stake in shares of Antares Pharma by 2,682.1% during the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock worth $6,530,000 after purchasing an additional 1,954,769 shares during the period. Hedge funds and other institutional investors own 34.63% of the company’s stock.
Shares of Antares Pharma (ATRS) traded up $0.05 during trading hours on Thursday, reaching $2.25. The company’s stock had a trading volume of 707,328 shares, compared to its average volume of 853,414. The firm has a market cap of $352.52, a PE ratio of -20.45 and a beta of 0.25. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09.
WARNING: This piece was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.truebluetribune.com/2018/01/21/zacks-analysts-expect-antares-pharma-inc-atrs-will-post-earnings-of-0-03-per-share.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.